{"filing":{"accession_number":"0001193125-26-407331","cik":"0001374690","ticker":"LRMR","company_name":"Larimar Therapeutics, Inc.","form":"8-K","filing_date":"2026-09-29","report_date":"2026-09-29","primary_document":"lrmr-20260929.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1374690/000119312526407331/lrmr-20260929.htm"},"events":[{"id":35738,"run_id":32937,"accession_number":"0001193125-26-407331","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The filing discloses the appointment of John B. Harlow, Jr. as President and Chief Operating Officer of Larimar Therapeutics, effective September 29, 2026. While the disclosure includes compensatory details (base salary of $560,000, signing bonus, equity grants of 800,000 options and 50,000 RSUs), the principal disclosed action is the appointment of a named executive officer to a senior leadership role. This is material to investors as it represents a significant change in the Company's executive leadership structure.","company_name":"Larimar Therapeutics, Inc.","ticker":"LRMR","filing_date":"2026-09-29","form":"8-K","submitted_at":null,"items":[{"id":39900,"accession_number":"0001193125-26-407331","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of John B. Harlow, Jr. as President and Chief Operating Officer of Larimar Therapeutics, effective September 29, 2026. While the disclosure includes compensatory details (base salary of $560,000, signing bonus, equity grants of 800,000 options and 50,000 RSUs), the principal disclosed action is the appointment of a named executive officer to a senior leadership role. This is material to investors as it represents a significant change in the Company's executive leadership structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T20:08:41.105840+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":39900,"accession_number":"0001193125-26-407331","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of John B. Harlow, Jr. as President and Chief Operating Officer of Larimar Therapeutics, effective September 29, 2026. While the disclosure includes compensatory details (base salary of $560,000, signing bonus, equity grants of 800,000 options and 50,000 RSUs), the principal disclosed action is the appointment of a named executive officer to a senior leadership role. This is material to investors as it represents a significant change in the Company's executive leadership structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T20:08:41.105840+00:00","company_name":"Larimar Therapeutics, Inc.","ticker":"LRMR","filing_date":"2026-09-29"}]}